Clinical trials: Restless Leg Syndrome (RLS)
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
Restless Legs Syndrome (RLS) study in adults comparing immediate release ropinirole with extended release ropinirole over 12 weeks
- Trial name
- NCT00314860
- Testing
- ropinirole Extended Release (XR)
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 568 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome
Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome
The purpose of this study is to assess the efficacy and safety of ropinirole XR in the treatment of adults with Restless Legs Syndrome (RLS).
- Trial name
- NCT00197080
- Testing
- Ropinirole Extended Release (XR)
- Where
- 70 sites in United States, Canada
- Volunteers
- 380 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome (RLS)
Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
To evaluate the safety, efficacy and pharmacokinetics of gabapentin enacarbil in moderate to severe primary RLS patients with moderate renal impairment and to confirm dosage and administration in such population.
- Trial name
- NCT01981941
- Testing
- Gabapentin enacarbil
- Where
- 5 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Astellas Pharma Inc
Restless Legs Syndrome
Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.
The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).
- Trial name
- NCT00311363
- Testing
- GEn (XP13512)
- Volunteers
- 327 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)
A 12 week clinical trial was conducted in the United States in order to compare pramipexole (Mirapex®) versus placebo for the ability to reduce the symptoms of restless legs syndrome in adult subjects.
- Trial name
- NCT00133198
- Testing
- Pramipexole
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)
The main goal of this open-label, prospective, non-controlled, non-interventional post marketing surveillance study is to evaluate how pramipexole treatment works when applied in actual practice.
- Trial name
- NCT00887289
- Where
- 784 sites in Germany
- Volunteers
- 1,504 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.
The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).
- Trial name
- NCT00298623
- Testing
- XP13512 (GSK1838262)
- Volunteers
- 222 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
The purpose of this study is to assess efficacy and safety of pregabalin in treating moderate to severe Restless Legs Syndrome in comparison to placebo.
- Trial name
- NCT01061372
- Testing
- pregabalin
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Restless Legs Syndrome
Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome
This is a clinical trial to be conducted at multiple sites in the USA. Patients diagnosed with moderate to severe Restless Legs Syndrome will be randomly allocated to one of 5 treatment arms in the study.
- Trial name
- NCT00834327
- Where
- 24 sites in United States
- Volunteers
- 230 people
- Sponsor
- Neurogen Corporation
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine
This double-blind study will evaluate the pharmacokinetics of a single dose of morphine or gabapentin derived from gabapentin enacarbil (GEn) after administration of morphine and GEn alone and in combination as well as the…
- Trial name
- NCT01476124
- Testing
- GEn 600 mg, Morphine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome
Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life
In this German non-interventional observational study 1980 patients diagnosed with Restless Legs Syndrome (RLS) will be investigated by 990 General Practitioners across all federal states in Germany.
- Trial name
- NCT00539461
- Where
- 317 sites in Germany
- Volunteers
- 2,023 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)
The purpose of this study is to determine whether IPX159 is safe and effective in treating symptoms of RLS in subjects with Restless Legs Syndrome.
- Trial name
- NCT01521663
- Testing
- IPX159
- Where
- 38 sites in United States
- Volunteers
- 159 people
- Sponsor
- Impax Laboratories, LLC
Restless Legs Syndrome
Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome
This study was designed to evaluate the safety, pharmacokinetic profile and efficacy in Restless Legs Syndrome patients.
- Trial name
- NCT00530790
- Testing
- ropinirole controlled release (CR)-RLS
- Where
- 11 sites in Japan
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome
ASP8825 - Study in Patients With Restless Legs Syndrome
To demonstrate the superiority of ASP8825 over placebo and the dose response in patients with restless legs syndrome
- Trial name
- NCT00530530
- Testing
- ASP8825
- Where
- 6 sites in Japan
- Volunteers
- 474 people
- Sponsor
- Astellas Pharma Inc
Restless Legs Syndrome
Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms
The main objective of this phase 2a proof-of-concept trial is to assess the efficacy of rotigotine nasal spray in ascending doses in subjects with idiopathic Restless Legs Syndrome.
- Trial name
- NCT00389831
- Testing
- Rotigotine Nasal Spray
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- UCB Pharma
Idiopathic Restless Legs Syndrome
A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome
The aims of the trial are to assess the safety and the efficacy of SPM 962 following once-a-daily transdermal administration within a range of 2.25 to 6.75 mg/day in Japanese patients with restless legs syndrome (RLS) in a…
- Trial name
- RLS (NCT01562743)
- Testing
- SPM 962
- Volunteers
- 185 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Restless Legs Syndrome
Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently approved in the United States for the treatment of adults with moderate-to-severe primary Restless Legs Syndrome (RLS).
- Trial name
- CONCORD (NCT01668667)
- Testing
- GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg
- Where
- 42 sites in United States
- Volunteers
- 501 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome, Multiple Sclerosis
Hypnosis and Direct Autonomic Experience Influence on Chronic Symptoms
Study will look at a limited number of participants with various chronic symptoms. Investigating a new and novel form of hypnosis application called "Direct Autonomic Experience (DAX)" which is using combination of visualization…
- Conditions
- Restless Legs Syndrome, Multiple Sclerosis, Trauma, Psychological, Chronic Disease
- Trial name
- HDAX1 (NCT04303143)
- Testing
- Self-Hypnosis, Direct Autonomic Experience Control
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Inner Group Inc.
Restless Legs Syndrome
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
The objectives of the Post Market Surveillance (PMS) study are to evaluate the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Rating Scale and Global Clinical…
- Trial name
- NCT00721279
- Testing
- Sifrol® (pramipexole dihydrochloride)
- Where
- 127 sites in Austria
- Volunteers
- 549 people
- Sponsor
- Boehringer Ingelheim